logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Magenta Therapeutics, Inc.


USPTO Granted Patents = 15


Forward Citations = 22

Loading Chart...
Loading Chart...

20 inventors (with patents filed for the assignee):

goldMedal Anthony Boitano (8 out of 21 patents)

silverMedal Michael P Cooke (6 out of 21 patents)

bronzeMedal Rahul Palchaudhuri (6 out of 11 patents)

4.  Dwight Morrow (4 out of 4 patents)

5.  Bradley R Pearse (4 out of 8 patents)

6.  Adam Hartigan (4 out of 4 patents)

7.  Sean McDonough (3 out of 6 patents)

8.  Rajiv Panwar (3 out of 7 patents)

9.  Arthur Glenn Romero (3 out of 38 patents)

10.  Andrew Nixon (2 out of 22 patents)

11.  Patrick C Falahee (2 out of 2 patents)

12.  Kevin A Goncalves (2 out of 2 patents)

13.  David Y Jackson (2 out of 18 patents)

14.  Edward Ha (2 out of 3 patents)

15.  Matthew Duncan Smith (2 out of 2 patents)


15 patents:

1. 12723097 - Anti-CD45 Antibody Drug Conjugates and Uses Thereof (2026-09-01),
2. 11572411 - Anti-CD117 antibodies and conjugates (2023-02-07),
3. 11260079 - Dosing regimens for the mobilization of hematopoietic stem and progenitor cells (2022-03-01),
4. 11229711 - Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use (2022-01-25),
5. 10919900 - Aryl hydrocarbon receptor antagonists and uses thereof (2021-02-16),
6. 10899843 - Compositions and methods for the depletion of CD117+ cells (2021-01-26),
7. 10882915 - Compositions and methods for the depletion of CD117+ cells (2021-01-05),
8. 10781259 - Modified antibodies and related compounds, compositions, and methods of use (2020-09-22),
9. 10624973 - Methods for the depletion of cells (2020-04-21),
10. 10576161 - Compositions and methods for the depletion of CD137+ cells (2020-03-03),
11. 10457683 - Aryl hydrocarbon receptor antagonists and uses thereof (2019-10-29),
12. 10434185 - Compositions and methods for the depletion of CD137+ cells (2019-10-08),
13. 10351572 - Aryl hydrocarbon receptor antagonists and uses thereof (2019-07-16),
14. 10111966 - Methods for the depletion of CD117+ cells (2018-10-30),
15. 10058573 - Dosing regimens for the mobilization of hematopoietic stem cells (2018-08-28),
Company Overview
Magenta Therapeutics, Inc. is a biotechnology company based in Cambridge, MA, focused on developing innovative therapies for patients with serious diseases. The company specializes in advancing targeted gene therapies and stem cell transplant technologies aimed at improving patient outcomes in areas such as cancer and autoimmune disorders. By leveraging its expertise in cellular and genetic engineering, Magenta seeks to transform the landscape of treatment options available to patients, enhancing the efficacy and safety of existing therapies.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Magenta Therapeutics, Inc. USPTO Patent Assignee Logo
15 Patents

#169 in Cambridge, MA

#1,276 in Massachusetts

#21,068 in US

#39,959 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Magenta Therapeutics, Inc.

Forward Citations = 22

20 inventors:

goldMedal Anthony Boitano (8 out of 21 patents)

silverMedal Michael P Cooke (6 out of 21 patents)

bronzeMedal Rahul Palchaudhuri (6 out of 11 patents)

4.  Dwight Morrow (4 out of 4 patents)

5.  Bradley R Pearse (4 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Magenta Therapeutics, Inc.. Retrieved from https://idiyas.com/company/magenta-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…